About us

The Winning Combination Inc. and Micropharma Limited are proud to bring to market Cardioviva™.

Founded in 1990, The Winning Combination Inc. is one of Canada’s leading Health and Wellness organizations with a focus on manufacturing and distributing natural health products and dietary supplements. The Winning Combination works closely with local governing regulatory bodies to ensure our products are of the highest quality and are in regulatory compliance in the markets in which we operate. Our facilities and manufacturing processes are fully compliant with GMP guidelines.

The Winning Combination operates in the food, drug, mass, specialty and convenience channels in the United States and Canada and is rapidly expanding its Global footprint through satellite organizations and strategic partnerships in countries such as Australia, New Zealand, Japan and China with planned future expansion into the European Union and Brazil.

Our portfolio of brands span the Vitamin and Dietary Supplements category, with brands focused on General Health and Wellness, Sports Nutrition, Heart Health, Joint Care, Weight Management and others. Over the years, The Winning Combination has developed strong partnerships and working relationships with key retail channels and is active in virtually all health related business channels.

The Winning Combination prides itself on being innovative and cutting edge in all aspects of business including procurement, formulation, manufacturing, product development, packaging design and sustainability. As a vertically integrated manufacturer, The Winning Combination can ensure unsurpassed product quality and speed in responding to any market changes. Our innovations have recently been featured in leading publications like Bloomberg, Wall Street Journal, Globe & Mail and Men’s Health.

For more information about The Winning Combination Inc. and its portfolio of brands and products, visit www.winning-combination.com.

Micropharma is specifically focused on products that address the healthy and natural metabolic balance and functioning of the microbiome, its resulting impact in the body and improving human health. The company will out-license these products to partners for commercialization in the medical food, consumer healthcare, and food ingredient markets.

Micropharma’ s proprietary technology platform is ProSelect™, a proprietary collection of bacteria, tools, high-throughput assays, and preclinical studies designed to screen and select bacteria for well-defined phenotypic traits that target metabolic pathways recognized as having therapeutic potential. Micropharma uses its novel fermentation and optimization techniques to activate genes and express traits of the organism that enhance the natural gut environment. Micropharma’s ProSelect enabling technology has built an intellectual property (IP) and product portfolio estate.

Cardioviva™ was developed through ProSelect, Micropharma’s proprietary discovery enabling technology that identifies non-GMO, probiotic candidates with the potential to promote better metabolic health and natural balance through the microbiome.

Micropharma’s product development approach is supported by extensive research to ensure that the most effective products are developed.

For more information about Micropharma and its portfolio of natural products, visit www.micropharma.net.

If you are interested in distributing Cardioviva™ outside of Canada and the United States, please contact:

Dr. Chris Wahl
Micropharma Limited
Tel: 514-524-2828
Fax: 514-227-5865